ARS Pharmaceuticals (SPRY) Return on Capital Employed: 2022-2025
Historic Return on Capital Employed for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to -0.31%.
- ARS Pharmaceuticals' Return on Capital Employed fell 1.00% to -0.31% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.31%, marking a year-over-year decrease of 1.00%. This contributed to the annual value of -0.01% for FY2024, which is 25.00% up from last year.
- Per ARS Pharmaceuticals' latest filing, its Return on Capital Employed stood at -0.31% for Q3 2025, which was down 43.85% from -0.22% recorded in Q2 2025.
- ARS Pharmaceuticals' Return on Capital Employed's 5-year high stood at -0.01% during Q4 2024, with a 5-year trough of -0.31% in Q3 2025.
- Its 3-year average for Return on Capital Employed is -0.22%, with a median of -0.26% in 2024.
- In the last 5 years, ARS Pharmaceuticals' Return on Capital Employed decreased by 15bps in 2023 and then increased by 27bps in 2024.
- ARS Pharmaceuticals' Return on Capital Employed (Quarterly) stood at -0.13% in 2022, then declined by 15bps to -0.28% in 2023, then rose by 27bps to -0.01% in 2024, then declined by 1bps to -0.31% in 2025.
- Its last three reported values are -0.31% in Q3 2025, -0.22% for Q2 2025, and -0.09% during Q1 2025.